Cipla: Sharp improvement in margins not likely to sustain
While the respiratory portfolio remains a significant part of the US portfolio, the peptides portfolio is a key watch in the near to medium term.
Latest News from Moneycontrol.com
How Privileged Access Tools Reduce Cybersecurity Risks












